Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether it is practical (feasible) to stop treatment with ropeg-interferon (ropeg-INF) for some people with polycythemia vera (PV) with a change (mutation) in theJa nus kinase 2 (JAK2) gene, based on how their disease responds to treatment.
Inclusion Criteria: * Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF). * Subject is willing and able to adhere to the study visit schedule and other protocol requirements. * Subjects must have been diagnosed with PV per WHO 2016 or WHO 2022 criteria within 12 months of enrollment and must not have received prior cytoreductive therapy other than hydroxyurea for \<6 months.54,55 Patients on hydroxyurea at the time of enrollment should discontinue hydroxyurea upon initiation of ropeg-IFN. If during the titration phase, the WBC and/or platelet counts increase t…
Patients will receive treatment with ropeg-IFN at previously established dosing subcutaneous every 2 weeks and escalated (within-person) as tolerated.